SERA
NASD Sera Prognostics, Inc. Class A$2.01 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.01, $0.07 below the day’s high of $2.08
- YTD change
- -31.86%
- vs 20-day SMA
- -1.82%
- vs 200-day SMA
- -12.36%
Price ranges
Price & Performance
+0.09 (+4.69%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 87.0% away from all-time highs of $15.50
- SERA is down 32% since the beginning of the year
- SERA is down 34% over the past 12 months
- SERA is down 3% over the past 1 month
- 1% of all SERA investors are betting against SERA
SERA reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -34.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -5.19%
- vs 8-day SMA
- -3.34%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.